Compound Profile: Ultima-Ipamorelin
Ipamorelin is a selective growth hormone secretagogue peptide that functions as a ghrelin receptor agonist in laboratory studies. This pentapeptide compound demonstrates highly selective activity at ghrelin receptors, stimulating growth hormone release without significantly affecting cortisol or prolactin levels in preclinical models. Researchers at Stroid UK Shop investigate this compound for its unique selectivity profile compared to other growth hormone releasing peptides. Ipamorelin’s molecular structure (CAS: 170851-70-4) allows for specific receptor binding characteristics that make it valuable for studying growth hormone axis modulation in controlled laboratory environments. The compound has progressed through Phase II clinical trials for post-surgical ileus, providing researchers with substantial data on its biological activity patterns and receptor selectivity mechanisms.
Laboratory Applications
Research scientists examine Ipamorelin for its selective ghrelin receptor agonism properties in various experimental protocols. Studies focus on understanding growth hormone release patterns, investigating receptor selectivity mechanisms, and analysing pulsatile hormone secretion dynamics. The compound’s ability to stimulate GH release while maintaining selectivity for specific receptor subtypes makes it particularly valuable for comparative studies with other peptides in growth hormone research. Laboratory investigations often involve examining the compound’s effects on circadian hormone patterns, studying receptor binding kinetics, and evaluating its potential applications in growth hormone deficiency research models. Researchers also investigate Ipamorelin alongside other compounds available in our SARMs collection to understand comparative mechanisms of action in various research contexts.
Technical Specifications
| Chemical Name | Ipamorelin |
|---|---|
| CAS Number | 170851-70-4 |
| Molecular Weight | 711.85 g/mol |
| Classification | Growth hormone secretagogue peptide |
| Purity | Research grade |
| Quantity | 5mg per vial |
| Storage | Lyophilised: -20°C, reconstituted: 2-8°C |
| Stability | Use within 30 days when reconstituted |
Researchers studying this compound often examine it alongside other peptides in our ipamorelin peptide category to compare selective receptor activity patterns and growth hormone release mechanisms.
Research Compliance
This product is manufactured by Ultima Peptides exclusively for in-vitro research applications and laboratory studies. Ipamorelin is not approved for human consumption, therapeutic use, or clinical applications outside of controlled research environments. All studies must be conducted by qualified researchers in appropriate laboratory facilities with proper safety protocols and institutional oversight. Purchase and use must comply with local regulations governing research chemical handling and laboratory safety requirements.
